Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Total Revenue of $2.04 million for fiscal year 2025.
Dianthus Therapeutics, Inc. /DE/ — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.04M -67.3% |
$6.24M +120.6% |
$2.83M | — | — | — |
| Revenue (ASC 606) | $2.04M -67.3% |
$6.24M +120.6% |
$2.83M | — | — | — |
| Net Income | -$162.34M -91.1% |
-$84.97M -95.1% |
-$43.55M -53.0% |
-$28.48M +60.0% |
-$71.14M +5.1% |
-$74.94M +2.4% |
| Diluted EPS | -$4.20 -64.7% |
-$2.55 +69.8% |
-$8.45 +74.1% |
-$32.57 -2424.8% |
-$1.29 +24.6% |
-$1.71 |
| Total Assets | $530.92M +42.0% |
$374.01M +108.5% |
$179.41M +115.9% |
$83.11M -56.2% |
$189.93M +17.5% |
$161.62M +0.1% |
| Cash and Equivalents | $51.09M +124.1% |
$22.79M -82.8% |
$132.32M +761.2% |
$15.37M -88.3% |
$131.65M +126.4% |
$58.15M -10.6% |
| Stockholders Equity | $493.40M +40.0% |
$352.48M +108.7% |
$168.87M +480.6% |
-$44.37M -157.2% |
-$17.25M -112.0% |
$143.91M +1.9% |
| R&D Expense | $145.64M +75.2% |
$83.11M +153.1% |
$32.84M +11.8% |
$29.38M -37.2% |
$46.77M -7.6% |
$50.62M -14.5% |
| Operating Income | -$177.93M -74.7% |
-$101.86M -111.5% |
-$48.17M -62.2% |
-$29.70M +60.2% |
-$74.69M +5.1% |
-$78.70M +5.1% |
| Shares Outstanding | 43.22M +38.9% |
31.12M +110.0% |
14.82M +1592.9% |
875,279 -98.5% |
58.80M +21.2% |
48.53M +23.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $396.0K | -81.8% | +105.2% |
| Revenue (ASC 606) | September 30, 2025 | $396.0K | -81.8% | +105.2% |
| Net Income | September 30, 2025 | -$36.77M | -46.0% | -16.2% |
| Diluted EPS | September 30, 2025 | -$0.97 | -31.1% | -10.2% |
| Total Assets | September 30, 2025 | $577.45M | +63.0% | +77.1% |
| Cash and Equivalents | September 30, 2025 | $55.98M | +66.3% | +322.9% |
| Stockholders Equity | September 30, 2025 | $546.45M | +61.7% | +80.3% |
| R&D Expense | September 30, 2025 | $32.49M | +27.2% | +23.8% |
| Operating Income | September 30, 2025 | -$40.29M | -34.7% | -15.3% |
| Shares Outstanding | September 30, 2025 | 42.85M | +45.9% | +33.2% |
- Dianthus Therapeutics, Inc. /DE/ reported Total Revenue of $2.04 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -67.3% in Total Revenue compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Revenue (ASC 606) of $2.04 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -67.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Net Income of -$162.34 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -91.1% in Net Income compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Diluted EPS of $4.20 per share (loss) for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -64.7% in Diluted EPS compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Total Assets of $530.92 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +42.0% in Total Assets compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Cash and Equivalents of $51.09 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +124.1% in Cash and Equivalents compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Stockholders Equity of $493.40 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +40.0% in Stockholders Equity compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported R&D Expense of $145.64 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +75.2% in R&D Expense compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Operating Income of -$177.93 million for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -74.7% in Operating Income compared to the prior fiscal year.
- Dianthus Therapeutics, Inc. /DE/ reported Shares Outstanding of 43.22 million shares for fiscal year 2025.
- Dianthus Therapeutics, Inc. /DE/ showed an increase of +38.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: